Nuwiq

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

simoktokog alfa

Available from:

Octapharma AB

ATC code:

B02BD02

INN (International Name):

simoctocog alfa

Therapeutic group:

Faktorji koagulacije krvi

Therapeutic area:

Hemofilija A

Therapeutic indications:

Zdravljenje in profilaksa krvavitve pri bolnikih s hemofilijo A (prirojeno pomanjkanje faktorja VIII). Nuwiq se lahko uporablja za vse starostne skupine.

Product summary:

Revision: 13

Authorization status:

Pooblaščeni

Authorization date:

2014-07-22

Patient Information leaflet

                                22
Zdravilo je lahko shranjeno pri sobni temperaturi (do 25 °C) za
enkratno obdobje, ki ni daljše od
1 meseca.
Zdravilo je bilo vzeto iz hladilnika: _____________
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Octapharma AB
Lars Forssells gata 23
112 75 Stockholm
Švedska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/14/936/001
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Nuwiq 250
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
23
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
OVOJNINAH
VIALA S PRAŠKOM
1.
IME ZDRAVILA IN POT(I) UPORABE
Nuwiq 250 i.e. prašek za raztopino za injiciranje
simoktokog alfa (humani rekombinantni koagulacijski faktor VIII)
Za intravensko uporabo po rekonstituciji.
2.
POSTOPEK UPORABE
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
6.
DRUGI PODATKI
Octapharma-Logo
24
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA
1.
IME ZDRAVILA
Nuwiq 500 i.e. prašek in vehikel za raztopino za injiciranje
simoktokog alfa (humani rekombinantni koagulacijski faktor VIII)
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
1 viala s praškom vsebuje 500 i.e. simoktokoga alfa (200 i.e./mL po
rekonstituciji).
3.
SEZNAM POMOŽNIH SNOVI
Pomožne snovi: saharoza, natrijev klorid, kalcijev klorid dihidrat,
argininijev klorid, natrijev citrat
dihidrat, poloksamer 188
Za nadaljnje informacije glejte navodila za uporabo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
prašek in vehikel za raztopino za injiciranje
1 viala s praškom, 1 napolnjena injekcijska brizga z 2,5 mL vode za
injekcije, 1 vmesnik za vialo,
1 igla z držalom v obliki metuljčka, 2 alkoholna zloženca
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Pred uporabo pre
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Nuwiq 250 i.e. prašek in vehikel za raztopino za injiciranje
Nuwiq 500 i.e. prašek in vehikel za raztopino za injiciranje
Nuwiq 1000 i.e. prašek in vehikel za raztopino za injiciranje
Nuwiq 1500 i.e. prašek in vehikel za raztopino za injiciranje
Nuwiq 2000 i.e. prašek in vehikel za raztopino za injiciranje
Nuwiq 2500 i.e. prašek in vehikel za raztopino za injiciranje
Nuwiq 3000 i.e. prašek in vehikel za raztopino za injiciranje
Nuwiq 4000 i.e. prašek in vehikel za raztopino za injiciranje
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Nuwiq 250 i.e. prašek in vehikel za raztopino za injiciranje
Ena viala vsebuje nominalno 250 i.e. humanega koagulacijskega faktorja
VIII (rDNK), simoktokoga
alfa.
Zdravilo Nuwiq 250 i.e. vsebuje po rekonstituciji približno 100
i.e./mL humanega koagulacijskega
faktorja VIII (rDNK), simoktokoga alfa.
Nuwiq 500 i.e. prašek in vehikel za raztopino za injiciranje
Ena viala vsebuje nominalno 500 i.e. humanega koagulacijskega faktorja
VIII (rDNK), simoktokoga
alfa.
Zdravilo Nuwiq 500 i.e. vsebuje po rekonstituciji približno 200
i.e./mL humanega koagulacijskega
faktorja VIII (rDNK), simoktokoga alfa.
Nuwiq 1000 i.e. prašek in vehikel za raztopino za injiciranje
Ena viala vsebuje nominalno 1000 i.e. humanega koagulacijskega
faktorja VIII (rDNK), simoktokoga
alfa.
Zdravilo Nuwiq 1000 i.e. vsebuje po rekonstituciji približno 400
i.e./mL humanega koagulacijskega
faktorja VIII (rDNK), simoktokoga alfa.
Nuwiq 1500 i.e. prašek in vehikel za raztopino za injiciranje
Ena viala vsebuje nominalno 1500 i.e. humanega koagulacijskega
faktorja VIII (rDNK), simoktokoga
alfa.
Zdravilo Nuwiq 1500 i.e. vsebuje po rekonstituciji približno 600
i.e./mL humanega koagulacijskega
faktorja VIII (rDNK), simoktokoga alfa.
Nuwiq 2000 i.e. prašek in vehikel za raztopino za injiciranje
Ena viala vsebuje nominalno 2000 i.e. humanega koagulacijskega
faktorja VIII (rDNK), simoktokoga
alfa.
Zdravilo Nuwiq 2000 i.e. vsebuje po rekonstituciji približn
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 07-11-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 07-11-2022
Public Assessment Report Public Assessment Report Bulgarian 17-01-2018
Patient Information leaflet Patient Information leaflet Spanish 07-11-2022
Public Assessment Report Public Assessment Report Spanish 17-01-2018
Patient Information leaflet Patient Information leaflet Czech 07-11-2022
Public Assessment Report Public Assessment Report Czech 17-01-2018
Patient Information leaflet Patient Information leaflet Danish 07-11-2022
Public Assessment Report Public Assessment Report Danish 17-01-2018
Patient Information leaflet Patient Information leaflet German 07-11-2022
Public Assessment Report Public Assessment Report German 17-01-2018
Patient Information leaflet Patient Information leaflet Estonian 07-11-2022
Public Assessment Report Public Assessment Report Estonian 17-01-2018
Patient Information leaflet Patient Information leaflet Greek 07-11-2022
Public Assessment Report Public Assessment Report Greek 17-01-2018
Patient Information leaflet Patient Information leaflet English 07-11-2022
Public Assessment Report Public Assessment Report English 17-01-2018
Patient Information leaflet Patient Information leaflet French 07-11-2022
Public Assessment Report Public Assessment Report French 17-01-2018
Patient Information leaflet Patient Information leaflet Italian 07-11-2022
Public Assessment Report Public Assessment Report Italian 17-01-2018
Patient Information leaflet Patient Information leaflet Latvian 07-11-2022
Public Assessment Report Public Assessment Report Latvian 17-01-2018
Patient Information leaflet Patient Information leaflet Lithuanian 07-11-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-11-2022
Public Assessment Report Public Assessment Report Lithuanian 17-01-2018
Patient Information leaflet Patient Information leaflet Hungarian 07-11-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 07-11-2022
Public Assessment Report Public Assessment Report Hungarian 17-01-2018
Patient Information leaflet Patient Information leaflet Maltese 07-11-2022
Public Assessment Report Public Assessment Report Maltese 17-01-2018
Patient Information leaflet Patient Information leaflet Dutch 07-11-2022
Public Assessment Report Public Assessment Report Dutch 17-01-2018
Patient Information leaflet Patient Information leaflet Polish 07-11-2022
Public Assessment Report Public Assessment Report Polish 17-01-2018
Patient Information leaflet Patient Information leaflet Portuguese 07-11-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 07-11-2022
Public Assessment Report Public Assessment Report Portuguese 17-01-2018
Patient Information leaflet Patient Information leaflet Romanian 07-11-2022
Public Assessment Report Public Assessment Report Romanian 17-01-2018
Patient Information leaflet Patient Information leaflet Slovak 07-11-2022
Public Assessment Report Public Assessment Report Slovak 17-01-2018
Patient Information leaflet Patient Information leaflet Finnish 07-11-2022
Public Assessment Report Public Assessment Report Finnish 17-01-2018
Patient Information leaflet Patient Information leaflet Swedish 07-11-2022
Public Assessment Report Public Assessment Report Swedish 17-01-2018
Patient Information leaflet Patient Information leaflet Norwegian 07-11-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 07-11-2022
Patient Information leaflet Patient Information leaflet Icelandic 07-11-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 07-11-2022
Patient Information leaflet Patient Information leaflet Croatian 07-11-2022
Public Assessment Report Public Assessment Report Croatian 17-01-2018

Search alerts related to this product

View documents history